Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence.
- Authors
- Benyamina, Amine; Bonhomme-Faivre, Laurence; Picard, Valérie; Sabbagh, Audrey; Richard, Damien; Blecha, Lisa; Rahioui, Hassan; Karila, Laurent; Lukasiewicz, Michael; Farinotti, Robert; Picard, Véronique; Marill, Catherine; Reynaud, Michel
- Year
- 2009
- Journal
- Progress in neuro-psychopharmacology & biological psychiatry
- PMID
- 19625010
- DOI
- 10.1016/j.pnpbp.2009.07.016
Prolonged cannabis use has a significant impact on health and well-being. Genetic factors are known to influence cannabis dependence, but few specific genetic markers have been identified. ABCB1 polymorphisms are known to modify drug pharmacokinetics but have yet to be studied for their role in generating and maintaining cannabis dependence. The objective of this study is to determine if ABCB1 C3435T polymorphism may represent an independent genetic marker for cannabis dependence risk. An open bi-centric association study was conducted in two French Addiction Centres. Caucasian patients diagnosed with isolated cannabis dependence were compared with healthy age-matched controls for socio-demographic, clinical and genetic data using chi-square test, Fisher's exact test, or Mann-Whitney U test. Independent association between ABCB1 C3435T SNP marker and cannabis dependence was evaluated using multiple logistic regression analysis. Versus controls (n=40), patients with cannabis dependence (n=40) had a significantly higher 3435C allele frequency (62.5% versus 43.8% respectively, P=0.017) and CC genotype (50% versus 20%, P=0.005, OR=4.00 [1.50-10.60]). Multiple logistic regression analysis of the C3435T SNP and variables identified in univariate analyses indicated that the CC genotype was independently associated with cannabis dependence (P=0.045, OR=6.61 [1.05-46.58]). This is the first time a significant specific genetic marker has been shown in cannabis dependence. ABCB1 polymorphisms may alter Delta9THC distribution, its psychoactive effects and individual vulnerability to dependence. These results pave the way to a new pharmacogenetic hypothesis in cannabis dependence.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| The genetic epidemiology of substance use disorder: A review. | 2017 | 28938182 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| <i>COMT</i> Genetic Variants and BDNF Level Associations with Cannabinoid Plasma Exposure: A Preliminary Study. | Manca A et al. | — | 2025 | → |
| Association of Dopamine Transporter Gene (DAT1) 40 bp 3' UTR VNTR Polymorphism (rs28363170) and Cannabis Use Disorder. | Olasore HS et al. | — | 2023 | → |
| Cannabis Pharmacogenomics: A Path to Personalized Medicine. | Babayeva M et al. | — | 2023 | → |
| Supporting Machine Learning Model in the Treatment of Chronic Pain. | Visibelli A et al. | — | 2023 | → |
| Association between <i>ABCB1</i> rs2235048 Polymorphism and THC Pharmacokinetics and Subjective Effects following Smoked Cannabis in Young Adults. | Matheson J et al. | — | 2022 | → |
| Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation. | Russo EB et al. | — | 2022 | → |
| Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. | Mills L et al. | — | 2022 | → |
| Review of delta-8-tetrahydrocannabinol (Δ<sup>8</sup> -THC): Comparative pharmacology with Δ<sup>9</sup> -THC. | Tagen M et al. | — | 2022 | → |
| The genetic aetiology of cannabis use: from twin models to genome-wide association studies and beyond. | Verweij KJH et al. | — | 2022 | → |
| Adolescent Δ<sup>9</sup>-Tetrahydrocannabinol Exposure and Astrocyte-Specific Genetic Vulnerability Converge on Nuclear Factor-κB-Cyclooxygenase-2 Signaling to Impair Memory in Adulthood. | Jouroukhin Y et al. | — | 2019 | → |
| Dark Classics in Chemical Neuroscience: Δ<sup>9</sup>-Tetrahydrocannabinol. | Banister SD et al. | — | 2019 | → |
| ABCB1 C3435T polymorphism is associated with tetrahydrocannabinol blood levels in heavy cannabis users. | Kebir O et al. | — | 2018 | → |
| Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review. | Bouquié R et al. | — | 2018 | → |
| Overlap of heritable influences between cannabis use disorder, frequency of use and opportunity to use cannabis: trivariate twin modelling and implications for genetic design. | Hines LA et al. | — | 2018 | → |
| Pharmacogenetics of Cannabinoids. | Hryhorowicz S et al. | — | 2018 | → |
| Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. | Silveira MM et al. | — | 2017 | → |
| The genetic epidemiology of substance use disorder: A review. | Prom-Wormley EC et al. | — | 2017 | → |
| ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment. | Liu H et al. | — | 2016 | → |
| Genome-wide association data suggest ABCB1 and immune-related gene sets may be involved in adult antisocial behavior. | Salvatore JE et al. | — | 2015 | → |
| Lack of association of DRD3 and CNR1 polymorphisms with premenstrual dysphoric disorders. | Yıldız M et al. | — | 2015 | → |
| Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. | Dennis BB et al. | — | 2014 | → |
| Genetic variants associated with addictive behavior in Colombian addicted and non-addicted to heroin or cocaine. | Isaza C et al. | — | 2013 | → |
| Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. | Hillard CJ et al. | — | 2012 | → |
| Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice. | Spiro AS et al. | — | 2012 | → |
| Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). | Ieiri I | — | 2012 | → |
| GHB and synthetic cathinones: clinical effects and potential consequences. | Karila L et al. | — | 2011 | → |
| Ultra-resistant schizophrenia is not associated with the multidrug-resistant transporter 1 (MDR1) gene rs1045642 variant. | Mouaffak F et al. | — | 2011 | → |
| Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis. | Bortolato M et al. | — | 2010 | → |
| Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. | Gassó P et al. | — | 2010 | → |